Hypertrophic Cardiomyopathy (HCM)

Sponsored diagnostic testing programs for Hypertrophic Cardiomyopathy (HCM)

Hypertrophic cardiomyopathy (HCM) is a genetic heart disorder marked by abnormal thickening of the heart muscle, most often the left ventricle. This can impair blood flow, cause arrhythmias, and lead to symptoms such as chest pain, shortness of breath, or fainting. Severity varies widely—from asymptomatic cases to significant cardiac complications.

2 programs found for Hypertrophic Cardiomyopathy (HCM)

Programs

2 programs
Invitae Unlock™

Invitae Arrhythmia and Cardiomyopathy Comprehensive Panel

The Invitae Unlock™ Cardiomyopathy & Arrhythmia program offers sponsored genetic testing for U.S. patients with suspected inherited cardiomyopathy or arrhythmia. The comprehensive panel supports diagnostic clarification, risk assessment, and family variant identification. The test is billed to insurance first; when a claim is denied or the patient is uninsured, the program's sponsor covers the cost of testing. Testing must be ordered by a qualified healthcare provider.

Cardiology
ViewOrder
Performing lab
Invitae | Labcorp
Hypertrophic Cardiomyopathy (HCM)
Roadmap2Rare
Sponsored by
Sanofi

Hypertrophic Cardiomyopathy (HCM) Panel

Roadmap2Rare (Canada) provides complimentary genetic and biochemical testing for suspected rare diseases, delivered by Revvity Omics in collaboration with Sanofi Canada. The program is designed to address unmet testing needs and is available to Canadian clinicians. Test selection and treatment decisions remain at the discretion of the healthcare professional.

Cardiology
ViewOrder
Performing lab
Revvity Omics, Inc.